Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.

A series of 7 H -pyrrolo[2,3- d pyrimidine derivatives possessing a dimethylphosphine oxide moiety were designed, synthesized and evaluated as novel Focal adhesion kinase (FAK) inhibitors. Most compounds potently suppressed the enzymatic activities of FAK, with IC 50 values in the 10−8–10−9 M range, and potently inhibited the proliferation of breast (MDA-MB-231) and lung (A549) cancer cell lines. The representative compound 25b exhibited potent enzyme inhibition (IC 50 = 5.4 nM) and good selectivity when tested on a panel of 26 kinases. 25b exhibited antiproliferative activity against A549 cells (IC 50 = 3.2 μ M) and relatively less cytotoxicity to a normal human cell line HK2. Compound 25b also induced apoptosis and suppressed the migration of A549 cells in a concentration-dependent manner. Further profiling of compound 25b revealed it had good metabolic stability in mouse, rat and human liver microsomes in vitro and showed weak inhibitory activity against various subtypes of human cytochrome P450. The docking study of compound 25b was performed to elucidate its possible binding modes and to provide a structural basis for further structure-guided design of FAK inhibitors. Image 1 • A series of 7 H -pyrrolo[2,3- d pyrimidine derivatives were designed and synthesized. • The compounds suppressed the enzymatic activities of FAK with IC 50 values of 10−8–10−9 M. • The compounds inhibited the proliferation of MDA-MB-231 and A549 cells. • 25b exhibited potent enzyme inhibition (IC 50 = 5.4 nM) and good selectivity. • 25b possessed good microsomal metabolic stability in vitro. [ABSTRACT FROM AUTHOR]